

Nivolumab CheckMate 067

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**




No QoL benefit

**Serious and disabling adverse effects**



**Other adjustments**



Long term plateau in the survival curve

Nivolumab CheckMate 067

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers  
 Therapeutic Indication: Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older\*  
 Experimental Arm: Nivolumab  
 Control Arm: Ipilimumab

